Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins

Takagi, Kan; Masuda, Kasumi; Yamazaki, Masamitsu; Kiyohara, Chikara; Itoh, Shinobu; Wasaki, Masahiko; Inoue, Hiroki

doi:10.5414/cnp73030

Cited by 53 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…bile acids, vitamin D, vitamin K) through intermolecular van der Waals attraction [31]. Indeed, sevelamer has been proven to bind the fat-soluble vitamin K in vitro, fully sequestering a test sample [32].…”

Section: Discussionmentioning

confidence: 99%

234: The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol

Pierce¹,

Pratt²,

Martin³

et al. 2010

American Journal of Kidney Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

234: The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol

Pierce¹,

Pratt²,

Martin³

et al. 2010

American Journal of Kidney Diseases

View full text Add to dashboard Cite

“…For example, sevelamer HCl adsorbs copper and zinc ions and a number of vitamins [37]. Therefore, in addition to having high efficacy, a low pill burden, and low risk of side effects, a phosphate binder should also have minimal interaction with other dietary nutrients.…”

Section: Vitamin D Metabolismmentioning

confidence: 99%

Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease

Sprague¹,

Marcuccilli²,

Rakov³

2015

Clinical Investigation

View full text Add to dashboard Cite

“…Our results confirm the role of sevelamer in decreasing both inflammation and event of stroke. Furthermore, sevelamer binds liposoluble Vitamins such as D and K [14]. By this way, sevelamer can act as a Vitamin K antagonist-like reducing the thromboembolic risk in these patients.…”

Section: Discussionmentioning

confidence: 99%

A Pharmacoeconomic Analysis of Phosphate Binders Cost-Effectiveness in the RISCAVID Study

Panichi

Rosati

et al. 2015

Blood Purif

View full text Add to dashboard Cite

Background: A pharmacoeconomic analysis of the RISCAVID database aimed at assessing the cost effectiveness of phosphate binders in preventing CV mortality and morbidity over 7 years was performed. Methods: Morbid or fatal events occurring in 750 chronic HD patients were recorded. Statistical analysis evaluated the distribution of variables and the effect of sevelamer on survival. A cost-effectiveness evaluation was performed using a probabilistic model based on a Markov chain. Results: Multivariate analysis showed that treatment with sevelamer was associated with a reduced stroke incidence by 52% (p = 0.04) and reduced levels of C-reactive protein (p < 0.01). Cost-effectiveness evaluation evidenced a 33% decrease in hospital-days for patients treated with sevelamer, with and without comorbidities compared to patients undergoing calcium binders treatment. Conclusion: Treatment withsevelamer was associated with a reduced risk of stroke in HD patients, with a clear saving on disease-related costs for the Italian National Healthcare System.

show abstract

Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins

Cited by 53 publications

References 0 publications

234: The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol

234: The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol

Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease

A Pharmacoeconomic Analysis of Phosphate Binders Cost-Effectiveness in the RISCAVID Study

Contact Info

Product

Resources

About